Related Experiment Video

Updated: Aug 20, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Adsorptive Monocyte-granulocytapheresis (M-GCAP) for refractory Crohn's disease

Takeshi Kusaka1, Ken Fukunaga, Kunio Ohnishi

  • 1The Division of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.

Journal of Clinical Apheresis
|December 15, 2004
PubMed

Insights

Monocyte-granulocytapheresis (M-GCAP) offers a potential adjunctive therapy for active Crohn's disease (CD) patients unresponsive to conventional medications. This apheresis treatment showed significant improvements in disease activity and quality of life for some patients.

Area of Science:

  • Immunology
  • Gastroenterology
  • Medical Technology

Background:

  • Active Crohn's disease (CD) poses challenges for patients unresponsive to conventional therapies.
  • Conventional medications (CM) often fail to induce remission in a significant subset of CD patients.
  • Exploring novel therapeutic approaches is crucial for managing refractory CD.

Purpose of the Study:

  • To evaluate the efficacy of Monocyte-granulocytapheresis (M-GCAP) as an adjunctive therapy for active CD patients.
  • To assess the impact of M-GCAP on Crohn's Disease Activity Index (CDAI) scores and quality of life.
  • To determine the specific cellular components removed during M-GCAP and their potential relevance.

Main Methods:

  • Six patients with active CD and high CDAI scores despite CM were enrolled.
  • A double series trial involving weekly M-GCAP sessions was conducted.
  • Patients were assessed for response based on CDAI score reduction and remission criteria (CDAI < 150).
  • Quality of life was measured using the Inflammatory Bowel Disease Questionnaire (IBDQ).

Main Results:

  • CDAI scores significantly decreased after the first M-GCAP series (258.2 to 166.5, P < 0.02).
  • Fifty percent of patients responded to M-GCAP, with one patient achieving remission.
  • Significant removal of white blood cells, particularly granulocytes, was observed.
  • Responders showed a statistically significant improvement in IBDQ scores (162.3 to 189.3, P < 0.03).

Conclusions:

  • M-GCAP can be an effective adjunctive therapy for active CD patients refractory to conventional treatments.
  • M-GCAP may help maintain a high quality of life in responsive CD patients.
  • Patients not achieving remission after the initial M-GCAP series may not benefit from further treatment.

More Related Videos

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity08:41

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity

Published on: June 7, 2017

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...